Individual investor Ben Baggett filed a Schedule 13G with the SEC on November 17, 2026, disclosing beneficial ownership of 300,000 shares of Cadrenal Therapeutics, Inc. common stock, representing 7.3% of the class, as of November 16, 2026.
Key Highlights
- Beneficial ownership: Ben Baggett reported aggregate beneficial ownership of 300,000 shares of Cadrenal Therapeutics, Inc. common stock.
- Percent of class: The 300,000 shares represent 7.3% of the outstanding class, according to the filing.
- Sole voting and dispositive power: Baggett reported sole voting power and sole dispositive power over all 300,000 shares, with no shared voting or dispositive power.
- Triggering event date: The date of the event requiring this filing was listed as November 16, 2026.
- Filer classification: Baggett identified himself as an individual investor, a United States citizen, residing in Clarksville, TN.
- Certification language: The filing states the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
Baggett's Schedule 13G Filing Details for Cadrenal Therapeutics Common Stock
According to the Schedule 13G filed November 17, 2026, Ben Baggett (full name listed in the filing as Baggett Benjamin Matthew Wall) disclosed beneficial ownership of 300,000 shares of Cadrenal Therapeutics, Inc. common stock, par value $0.001 per share (CUSIP: 127636207). The filing identifies Cadrenal Therapeutics, Inc. as the issuer, with principal executive offices at 822 A1A North, Suite 306, Ponte Vedra, Florida, 32082. The ticker symbol for Cadrenal Therapeutics listed in the filing context is NASDAQ:CVKD.
The filing reports that Baggett holds sole voting power and sole dispositive power over all 300,000 shares, with zero shares subject to shared voting or shared dispositive power. The 300,000 shares represent 7.3% of the class. Baggett's address is listed as 2807 Rome Lane, Clarksville, TN 37040, and his type of reporting person is designated as "IN" (individual).
In the certification included in Item 10, Baggett stated that to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of changing or influencing control of Cadrenal Therapeutics, except as may relate to activities solely in connection with a nomination under Section 240.14a-11. Items 5 through 9 of the filing, covering ownership on behalf of another person, subsidiary identification, and group membership, are each marked "Not Applicable."
What Was Disclosed
Ben Baggett filed a Schedule 13G disclosing beneficial ownership of 300,000 shares, equal to 7.3% of Cadrenal Therapeutics, Inc. common stock, with all voting and dispositive power held solely by Baggett as of November 16, 2026.



Please wait processing your request...